119511-77-2

Usage

Ethyl ester derivative

1-amino-2,3-dihydro-1H-indene-1-carboxylic acid The compound is derived from 1-amino-2,3-dihydro-1H-indene-1-carboxylic acid by attaching an ethyl ester group.

Pharmaceutical industry use

Precursor in the synthesis of various pharmaceuticals and related compounds The compound is commonly used as a starting material for creating other drugs and medicinal compounds.

Research and development application

New drug and medication development The compound is also utilized in research and development efforts for creating novel pharmaceuticals and medications.

Stability

Ethyl ester form The ethyl ester form of the compound provides increased stability, making it more suitable for handling, storage, and use in chemical reactions.

Ease of handling and storage

Due to its stability, the ethyl ester form of 1H-Indene-1-carboxylic acid, 1-amino-2,3-dihydrois easier to handle and store compared to other forms of the compound.

Role in drug development and synthesis

Important contribution The chemical compound plays a significant role in the development and synthesis of pharmaceuticals, making it a valuable asset in the field.

Upstream product

• 64-17-5 ethanol 
• 3927-71-7 1-amino-2,3-dihydro-1H-indene-1-carboxylic acid 
• 6252-98-8 spiro[imidazolidine-4,1'-indan]-2,5-dione 

Downstream Products

• 879319-16-1 (S)-2-(2,5-dioxo-2',3'-dihydrospiro[imidazolidine-4,1'-indene]-1-yl)acetic acid 
• 166735-12-2 (S)-methyl 1-amino-2,3-dihydro-1H-indene-1-carboxylate 

Relevant academic research and scientific papers

Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases

P300 and its paralog CBP can acetylate histones and other proteins and have been implicated in a number of diseases characterized by aberrant gene activation, such as cancer. A novel, highly selective, orally bioavailable histone acetyltransferase (HAT) domain inhibitor has been identified through virtual ligand screening and subsequent optimization of a unique hydantoin screening hit. Conformational restraint in the form of a spirocyclization followed by substitution with a urea led to a significant improvement in potency. Replacement of the hydantoin moiety with an oxazolidinedione followed by fluoro substitution led to A-485, which exhibits potent cell activity, low clearance, and high oral bioavailability.

SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE

Compounds having a structure of Formula (IX) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.

Candida antarctica Lipase B in a chemoenzymatic route to cyclic α-quaternary α-amino acid enantiomers

Kinetic resolution of three cyclic quaternary ethyl 1-amino-2,3-dihydro-1H- indene-1-carboxylates and both 1- and 2-amino-1,2,3,4-tetrahydronaphthalene analogues have been studied. Interesterification with butyl butanoate and Candida antarctica lipase B accomplished the task. The enantiomers of all 1-amino analogues reacted with excellent enantioselectivity (enantiomeric ratio er greater than 200), whereas the 2-amino analogue was not enantioselective (er = 4). Amino acid enantiomers were finally obtained as their respective hydrochlorides with almost maximum theoretical yields. For the first time, a lipase enzyme was effectively used in the kinetic resolution of cyclic α-quaternary α-amino esters. Copyright

ANTI-VIRAL COMPOUNDS

Compounds effective in inhibiting replication of Hepatitis C virus ( HCV ) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, coformulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.